PUBLISHER: Grand View Research | PRODUCT CODE: 2040634
PUBLISHER: Grand View Research | PRODUCT CODE: 2040634
The global blood group typing market size was valued at USD 2.31 billion in 2025 and is projected to reach USD 5.59 billion by 2033, growing at a CAGR of 11.99% from 2026 to 2033. Market growth is driven by the rising burden of chronic diseases such as anemia, cancer, and blood disorders, which increases the need for frequent transfusions.
In addition, the growing number of surgical procedures, organ transplants, and trauma cases is further driving demand for accurate blood compatibility testing. The high burden of chronic diseases such as anemia, cancer, and hematological disorders is a significant driver of the blood group typing market, as these conditions often require frequent blood transfusions. For instance, according to a World Health Organization report published in 2025, anemia affects nearly 30% of women of reproductive age and around 40% of children under five globally, highlighting a substantial patient pool requiring transfusion support. Similarly, increasing cancer incidence and blood disorders such as thalassemia and sickle cell disease are contributing to repeated transfusion needs. This growing transfusion volume necessitates accurate ABO and Rh typing to ensure compatibility and prevent adverse reactions. Consequently, the rising prevalence of these chronic conditions is significantly accelerating demand for advanced blood group typing solutions worldwide.
The growing number of surgical procedures, organ transplants, and trauma cases is driving the demand for accurate blood compatibility testing, thereby supporting the growth of the blood group typing market. For instance, according to the World Health Organization (December 2023), around 1.2 million people die each year due to road traffic accidents, while many sustain non-fatal injuries and many require emergency transfusions. In addition, the number of organ transplant procedures has increased globally. According to an article published in PubMed in 2026, 173,727 solid organ transplants were performed worldwide in 2024, and these statistics were reported by the Global Observatory on Donation and Transplantation, an initiative of the WHO. These clinical situations require precise ABO and Rh typing and cross-matching to ensure patient safety. As the volume of surgeries and emergency care continues to rise, the need for reliable blood group typing solutions is also increasing.
Expanding blood donation programs and increasing transfusion volumes are contributing to the demand for routine blood group typing and compatibility testing. For instance, according to the statistics published by the World Health Organization in May 2025, over 118.5 million blood donations are collected globally each year, all of which require mandatory blood grouping and screening before use. In addition, advancements in molecular and automated typing technologies, including PCR-based genotyping, are improving accuracy and reducing turnaround time. The growing use of blood group typing in prenatal testing for diagnosing hemolytic disease of the newborn (HDN), along with stricter regulatory standards for transfusion safety, is further supporting the adoption of advanced typing solutions, thereby supporting overall market expansion. However, stringent approval processes and varying regulatory frameworks across regions can delay product launches and market entry.
Global Blood Group Typing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood group typing market report based on product, techniques, test type, and region: